Advertisement

Author: Staff

NuVasive reported a second quarter revenue increase of 35.2 percent over last year's second quarter, and a 9.6 percent increase over the first quarter of 2010 due in part to adopting XLIF technology, according to a NuVasive news report.

After the Food and Drug Administration initially expressed concern about the high cancer rates among clinical study patients receiving Medtronic's Amplify for posterlateral lumbar fusion, the FDA's Orthopaedic and Rehabilitation Devices panel voted 6-5 in favor of approval, according to…

Advertisement
Advertisement